Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14,381 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia.
Short NJ, Borthakur G, Pemmaraju N, Dinardo CD, Kadia TM, Jabbour E, Konopleva M, Macaron W, Ning J, Ma J, Pierce S, Alvarado Y, Sasaki K, Takahashi K, Estrov Z, Masarova L, Issa GC, Montalban-Bravo G, Andreeff M, Burger JA, Miller D, Alexander L, Naing A, Garcia-Manero G, Ravandi F, Daver N. Short NJ, et al. Among authors: miller d. Leuk Lymphoma. 2022 Sep;63(9):2161-2170. doi: 10.1080/10428194.2022.2062345. Epub 2022 Apr 20. Leuk Lymphoma. 2022. PMID: 35442137 Clinical Trial.
Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents.
Jabbour E, Faderl S, Sasaki K, Kadia T, Daver N, Pemmaraju N, Patel K, Khoury JD, Bueso-Ramos C, Bohannan Z, Ravandi F, Borthakur G, Verstovsek S, Miller D, Maduike R, Hosing C, Kantarjian HM, Garcia-Manero G. Jabbour E, et al. Among authors: miller d. Cancer. 2017 Feb 15;123(4):629-637. doi: 10.1002/cncr.30383. Epub 2016 Oct 14. Cancer. 2017. PMID: 27741352 Free article. Clinical Trial.
Major clinical response in a patient with leukemia cutis treated with the bromodomain inhibitor PLX51107 and azacitidine.
Kim K, Bazinet A, Loghavi S, Konopleva M, Bhalla K, Daver N, Khoury JD, Kadia T, Wilson NR, Curry JL, Heberton M, Miller D, Pierce S, Borthakur G, Pemmaraju N. Kim K, et al. Among authors: miller d. Leuk Res. 2022 Aug;119:106884. doi: 10.1016/j.leukres.2022.106884. Epub 2022 May 31. Leuk Res. 2022. PMID: 35691130 No abstract available.
Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies.
Senapati J, Fiskus WC, Daver N, Wilson NR, Ravandi F, Garcia-Manero G, Kadia T, DiNardo CD, Jabbour E, Burger J, Short NJ, Alvarado Y, Jain N, Masarova L, Issa GC, Qiao W, Khoury JD, Pierce S, Miller D, Sasaki K, Konopleva M, Bhalla KN, Borthakur G, Pemmaraju N. Senapati J, et al. Among authors: miller d. Clin Cancer Res. 2023 Nov 1;29(21):4352-4360. doi: 10.1158/1078-0432.CCR-23-1429. Clin Cancer Res. 2023. PMID: 37585491
Baseline Skin Microbiota of the Leatherback Sea Turtle.
Kuschke SG, Wyneken J, Miller D. Kuschke SG, et al. Among authors: miller d. Microorganisms. 2024 May 1;12(5):925. doi: 10.3390/microorganisms12050925. Microorganisms. 2024. PMID: 38792755
Large-scale mutational analysis identifies UNC93B1 variants that drive TLR-mediated autoimmunity in mice and humans.
Rael VE, Yano JA, Huizar JP, Slayden LC, Weiss MA, Turcotte EA, Terry JM, Zuo W, Thiffault I, Pastinen T, Farrow EG, Jenkins JL, Becker ML, Wong SC, Stevens AM, Otten C, Allenspach EJ, Bonner DE, Bernstein JA, Wheeler MT, Saxton RA; Undiagnosed Diseases Network; Liu B, Majer O, Barton GM. Rael VE, et al. J Exp Med. 2024 Aug 5;221(8):e20232005. doi: 10.1084/jem.20232005. Epub 2024 May 23. J Exp Med. 2024. PMID: 38780621 Free PMC article.
14,381 results
You have reached the last available page of results. Please see the User Guide for more information.